Gotowa bibliografia na temat „HCV”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Spis treści
Zobacz listy aktualnych artykułów, książek, rozpraw, streszczeń i innych źródeł naukowych na temat „HCV”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Artykuły w czasopismach na temat "HCV"
CRAMP, M. E. "HBV + HCV = HCC?" Gut 45, nr 2 (1.08.1999): 168–69. http://dx.doi.org/10.1136/gut.45.2.168.
Pełny tekst źródłaMujeeb, Syed Abdul, Qamar Jamal, Rafique Khanani, Nayyer Iqbal i Shahnaz Kaher. "Prevalence of Hepatitis B Surface Antigen and HCV Antibodies in Hepatocellular Carcinoma Cases in Karachi, Pakistan". Tropical Doctor 27, nr 1 (styczeń 1997): 45–46. http://dx.doi.org/10.1177/004947559702700117.
Pełny tekst źródłaStroffolini, Tommaso, i Giacomo Stroffolini. "A Historical Overview on the Role of Hepatitis B and C Viruses as Aetiological Factors for Hepatocellular Carcinoma". Cancers 15, nr 8 (20.04.2023): 2388. http://dx.doi.org/10.3390/cancers15082388.
Pełny tekst źródłaHuang, Yen-Tsung, Chin-Lan Jen, Hwai-I. Yang, Mei-Hsuan Lee, Jun Su, Sheng-Nan Lu, Uchenna H. Iloeje i Chien-Jen Chen. "Lifetime Risk and Sex Difference of Hepatocellular Carcinoma Among Patients With Chronic Hepatitis B and C". Journal of Clinical Oncology 29, nr 27 (20.09.2011): 3643–50. http://dx.doi.org/10.1200/jco.2011.36.2335.
Pełny tekst źródłaPár, Alajos. "Prophylaxis and treatment of chronic viral hepatitis as the prevention of hepatocellular carcinoma". Orvosi Hetilap 150, nr 1 (1.01.2009): 19–26. http://dx.doi.org/10.1556/oh.2009.28529.
Pełny tekst źródłaHaberl, Elisabeth M., Thomas S. Weiss, Georg Peschel, Kilian Weigand, Nikolai Köhler, Josch K. Pauling, Jürgen J. Wenzel i in. "Liver Lipids of Patients with Hepatitis B and C and Associated Hepatocellular Carcinoma". International Journal of Molecular Sciences 22, nr 10 (18.05.2021): 5297. http://dx.doi.org/10.3390/ijms22105297.
Pełny tekst źródłaFang, Lily, Amanda Yu i Jane A. Buxton. "Identification of Acute Vaccine-Preventable Hepatitis in Individuals with Chronic Hepatitis in British Columbia between 1991 and 2007". Canadian Journal of Infectious Diseases and Medical Microbiology 22, nr 1 (2011): 10–14. http://dx.doi.org/10.1155/2011/564290.
Pełny tekst źródłaBuxton, Jane A., i Jin Hee Kim. "Hepatitis A and Hepatitis B Vaccination Responses in Persons with Chronic Hepatitis C Infections: A Review of the Evidence and Current Recommendations". Canadian Journal of Infectious Diseases and Medical Microbiology 19, nr 2 (2008): 197–202. http://dx.doi.org/10.1155/2008/410362.
Pełny tekst źródłaShen, Yu-Chuan, Hui-Ching Hsu, Tzu-Min Lin, Yu-Sheng Chang, Li-Fang Hu, Lung-Fang Chen, Sheng-Hong Lin i in. "H1-Antihistamines Reduce the Risk of Hepatocellular Carcinoma in Patients With Hepatitis B Virus, Hepatitis C Virus, or Dual Hepatitis B Virus-Hepatitis C Virus Infection". Journal of Clinical Oncology 40, nr 11 (10.04.2022): 1206–19. http://dx.doi.org/10.1200/jco.21.01802.
Pełny tekst źródłaAlhamadany, Alaa Younis Mahdy, i Wajdi Sabeeh Sadek. "Analysis of the Chromosomal Aberrations in Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), and Hepatocellular Carcinoma Patients (HCC) in Mosul City, Iraq". NTU Journal of Pure Sciences 1, nr 2 (31.05.2022): 48–53. http://dx.doi.org/10.56286/ntujps.v1i2.210.
Pełny tekst źródłaRozprawy doktorskie na temat "HCV"
Soares, Sampaio Aletheia. "Marcadores sorológicos para os vírus da hepatite B e C em pacientes HIV-positivos atendidos no Hospital Universitário Oswaldo Cruz". Universidade Federal de Pernambuco, 2005. https://repositorio.ufpe.br/handle/123456789/7445.
Pełny tekst źródłaA ocorrência de co-infecção pelo HIV e hepatites B e C tem sido relatada desde a era- HAART (do inglês Highly Active Antinetrovial Therapy), quando a mortalidade nas pessoas infectadas pelo HIV começou diminuir. Como conseqüência do fato de terem as mesmas rotas de transmissão, a co-infecção do HBV ou HCV em pessoas infectadas pelo HIV tem aumentado e tornou-se um problema de saúde pública. No Brasil, a prevalência média da coinfecção HIV e hepatites, encontrada pelo Ministério da Saúde é em torno de 40%, com a maioria em grupos de usuários de drogas. Freqüências variáveis de co-infecção têm sido relatadas, dependendo da população e da região estudada. O objetivo principal deste estudo foi identificar a freqüência de marcadores sorológicos para hepatite B e C em pacientes infectados pelo HIV, acompanhados em um hospital escola e os possíveis fatores associados à presença de tais marcadores. Quatrocentos e vinte e nove pacientes foram estudados, de ambos os sexos e com idade variando entre 18 a 77 anos. Os participantes respondiam um questionário específico, com características sócio-demográficas e tinham uma amostra de sangue testada para os marcadores HBsAg, Anti-HBc total e Anti-HCV, utilizando a técnica MEIA-Axym-Abbott. A freqüência encontrada de marcadores foi 10,3% para o HBsAg, 38,7% para o Anti-HBc total e 10,7% para o Anti-HCV. Dentre os pacientes, 1,4% possuíam tanto HBsAg quanto Anti-HCV positivos. Não houve associação significante estatisticamente entre as variáveis parceiro homossexual, uso de drogas endovenosas, ingesta de álcool, tatuagem ou piercing, cirurgia, procedimentos invasivos e hemotransfusão e a infecção pelo HBV, expressa pela positividade do HBsAg. A única variável que mostrou associação com infecção pelo HBV foi uso de drogas inalatórias. Nenhuma destas variáveis, incluindo, parceiro homossexual, uso de drogas endovenosas, uso de drogas inalatórias, ingesta de álcool, tatuagem ou piercing, cirurgia, procedimentos invasivos e hemotransfusão tiveram associação significativa estatisticamente com a presença do Anti-HCV. Este estudo encontrou freqüências comparáveis com outros relatados no Brasil, mas com freqüências de coinfeccção menores que aqueles das regiões Sul e Sudeste. Entretanto, nenhuma associação específica com comportamentos de risco foi encontrada neste estudo, mostrando importante diferença quando comparado com estudos realizados em outras regiões do Brasil
Burke, Stephanie. "Generalized Impairment of CD8+ T-cells in HCV Mono- and HIV-HCV Co-infection". Thesis, Université d'Ottawa / University of Ottawa, 2015. http://hdl.handle.net/10393/32770.
Pełny tekst źródłaKleefeld, Felix [Verfasser]. "Untersuchung des Einflusses einer Interferon-freien HCV-Eradikation auf neurokognitive Funktionen in HIV/HCV-koinfizierten und HCV-monoinfizierten Patienten / Felix Kleefeld". Berlin : Medizinische Fakultät Charité - Universitätsmedizin Berlin, 2019. http://d-nb.info/1179778103/34.
Pełny tekst źródłaGupta, Priyanka. "Host gene expression and its regulation by microRNA in HCV and HIV/HCV co-infection". Thesis, The University of Sydney, 2014. http://hdl.handle.net/2123/11998.
Pełny tekst źródłaRUSSO, DARIO. "Diagnosi parallela automatizzata di infezioni virali trasmissibili per via ematica (HIV, HCV, HBV)". Doctoral thesis, Università degli Studi di Milano, 2007. http://hdl.handle.net/2434/33618.
Pełny tekst źródłaSouza, Iury Oliveira. "Validação de ensaio imunocromatográfico para a detecção múltipla de anticorpos específicos contra HIV, HBV e HCV". reponame:Repositório Institucional da UFBA, 2013. http://www.repositorio.ufba.br/ri/handle/ri/11787.
Pełny tekst źródłaMade available in DSpace on 2013-06-10T18:28:37Z (GMT). No. of bitstreams: 1 Dissertação_ICS_Iury Souza.pdf: 1047267 bytes, checksum: 06bc8acdb629b7e8ae63feab201995ad (MD5)
CAPES
Cerca de 33,3 milhões de pessoas apresentam infecção pelo Human Immunodeficiency Virus (HIV) no mundo; 180 milhões estão infectados pelo Hepatitis C Virus HCV e estima-se que 360 milhões apresentem infecção ativa pelo Hepatitis B Virus (HBV). Outra realidade mundial é a co-infecção entre esses vírus. Os dados mostram a importância global dessas viroses e a urgência do desenvolvimento de novos ensaios de diagnóstico sensíveis, específicos, rápidos e de baixo custo, que possam atender à demanda de entidades públicas inseridas em programas para prevenção e diagnostico dessas doenças. O presente trabalho consiste em validação relativa de um novo teste imunocromatográfico desenvolvido pela empresa canadense Medmira para detecção de anticorpos específicos contra HIV, HCV e HBV. Os resultados encontrados foram extremamente favoráveis para a detecção de anticorpos específicos para HIV, apresentando 98,6% de sensibilidade e 100% de especificidade. Para o anti-HBV a sensibilidade e especificidade encontradas foram de 90,0% e 98,6%, e de 86,3% e 100%, para anti-HCV, respectivamente. Nenhuma reatividade cruzada foi encontrada e a reprodutibilidade e repetitividade foram de 100%. O índice kappa e a acurácia global do teste foram de 0,91 (0,88-0,94) e 95,5% (93,5-97,5), respectivamente. Conclui-se que o ensaio imunocromatográfico é clinicamente útil em triagens rápidas para detecção de anticorpos anti-HIV, HCV e HBV.
Salvador
Heller, Sophie [Verfasser]. "Untersuchung visueller Aufmerksamkeitsparameter vor und nach einer Hepatitis C (HCV)-Therapie mit Direct Antiviral Agents bei HCV-monoinfizierten und HCV/HIV-koinfizierten Patienten / Sophie Heller". Berlin : Medizinische Fakultät Charité - Universitätsmedizin Berlin, 2020. http://d-nb.info/1206186070/34.
Pełny tekst źródłaHultgren, Catharina. "Immune modulation in chronic HBV and HCV infection /". Stockholm, 2000. http://diss.kib.ki.se/2000/91-628-4255-2/.
Pełny tekst źródłaCosta, Cintia Bezerra Almeida. "Polimorfismo do HLA-G na coinfecção HIV/HCV". Universidade de São Paulo, 2014. http://www.teses.usp.br/teses/disponiveis/22/22132/tde-21052014-181750/.
Pełny tekst źródłaThe general objective of the research was to associate the polymorphism of the gene HLA-G (region 3\' NT) with the co-infection HIV/HCV and with the groups (HIV, HCV and healthy control). It is a cross-sectional, comparative, descriptive study. 560 individuals participated of the study, being 156 healthy control individuals, 102 co- infected HIV/HCV, 186 infected by HIV and 116 by HCV. For identifying the polymorphisms, the genomic DNA was extracted from the total blood and the genotyping was made by PCR and visualized in gel of polyacrylamide at 7%, in which the polymorphism of 14pb was identified, and by sequencing the other seven SNPs. The social demographic results point that the most of the sample was composed by male adult individuals. Regarding the color of the skin, in the comparison between the groups HCV and HIV/HCV, a bigger number of co-infected with black skin and brown-skinned was observed than in the mono infected (P=0,0001). Regarding to the category of exposition for acquisition of the HIV, in the comparison between the groups HIV and HIV/HCV, a significant difference was observed in the transmission through heterosexual exposition, being its frequency bigger in the group HIV (P=0,0000). In the case of the comparison between the groups HCV and HIV/HCV, the difference in the heterosexual transmission was also observed, being its frequency significantly higher in the group HIV/HCV (P=0,0001). About the finding related to the genotype of the HCV, in the comparison between the groups HCV and HIV/HCV, the genotype 1a presented higher frequency in the co- infected (P=0,0001). Regarding to the viral load of the HIV, in the comparison between the groups HIV and HIV/HCV, the group of the mono infection presented bigger viral load that the group of the co-infection (P=0,0350). Regarding to the level of hepatic fibrosis, in the comparison between the groups HCV and HIV/HCV, the group of co-infection has a lighter fibrosis that the group of the mono infection (P=0,0009). Regarding to the genetic polymorphisms of the region 3\' NT of the HLA-G, it was found that the genotype of heterozygosis Del/Ins of 14 pb, presented significant difference in the individuals co-infected by the HIV/HCV (P=0,0216) when compared with the control group. About the SNP +3003, the comparison of the groups HCV and healthy control, it was showed that the allele +3003T presented a significant higher frequency in the group HCV (P=0,0147); the genotype +3003C/T presented a higher frequency in the control group (P=0,0095); the genotype +3003T/T was bigger in the group HCV (P=0,0095). The comparison between the groups HIV and HCV showed that the frequency of the allele +3003C was bigger in the group HIV (P=0,0463); and the genotype +3003T/T presented a bigger frequency in the group (P=0,0494). The frequency of the genotype +3187A/A was bigger in the group HIV/HCV in comparison to the HIV (P=0,0193); and of the +3187A/G was bigger in the group HIV (P=0,0187). The genotype +3196C/G presented frequency significantly bigger in the group HIV than in the healthy control (P=0,0213). The UTR-10, in comparison between the groups HIV and control, showed bigger frequency in the group HIV (P=0,0044); when compared the groups HIV/HCV and HIV, frequency was bigger in the group HIV (P=0,0300) and in the comparison between the groups HIV and HCV, its frequency was also bigger in the group (P=0,0140). The UTR-4, in the comparison of the groups HCV and healthy control, revealed a bigger frequency in the control group (P=0,0147). The UTR-9, in comparison of the groups HIV/HCV and HIV, showed bigger frequency in the group HIV/HCV (P=0,0460). Regarding to the clinical data, the presence of the allele T in the position +3035, was significantly associated to bigger viral load of the HCV, above 400.000 copies /mL (P=0,0244). About the types of genotypes of the HCV, the presence of the allele +3027C was associated with the subtype 1a of the HCV (P=0,0109). Additionally, the presence of the genotype C/C in the position +3027 was also significantly associated with the subtype 1a of the HCV (P=0,0015). Still, the allele A of the SNP +3187 was significantly associated with the other genotypes of the HCV, excluding the 1a (P=0,0369). Although the function of the gene HLA-G, is not totally clarified, studies have been developed for better elucidate its function in the physiological contexts, like gestation, and pathological, such as tumours, transplants, infectious and inflammatory diseases. These studies aim to extend the knowledge about the immunological system and contribute for the development of new diagnostic and therapeutic strategies. The results of this study contribute for enhancement of the knowledge about the polymorphisms of the region 3\' NT of the gene HLA-G, in the co-infection HIV/HCV. As well as, in the improvement of the assistance of nursing that must seek reducing the morbid mortality by the pathology referred. However, there is still a long path to be followed in the comprehension of the immunogenic factors involved in the co-infection by the HIV/HCV
Uccellini, L. "HOST GENETIC INFLUENCE ON HIV AND HCV INFECTIONS". Doctoral thesis, Università degli Studi di Milano, 2013. http://hdl.handle.net/2434/215587.
Pełny tekst źródłaKsiążki na temat "HCV"
Thiemann, Lillian. Double jeopardy: The HIV/HCV co-infection handbook. New York: Community Prescription Service, 1999.
Znajdź pełny tekst źródłaDammacco, Franco, red. HCV Infection and Cryoglobulinemia. Milano: Springer Milan, 2012. http://dx.doi.org/10.1007/978-88-470-1705-4.
Pełny tekst źródłaDammacco, Franco. HCV Infection and Cryoglobulinemia. Milano: Springer-Verlag Italia, 2012.
Znajdź pełny tekst źródłaMusharraf, Husain, i Population Council (Bangladesh), red. Prevalence of HIV, HBV, HCV and syphilis markers in pregnant women of Bangladesh. Dhaka, Bangladesh: Population Council, 1997.
Znajdź pełny tekst źródłaOkita, Kiwamu, red. HCV and Related Liver Diseases. Tokyo: Springer Japan, 1999. http://dx.doi.org/10.1007/978-4-431-68488-6.
Pełny tekst źródłaJürgens, Ralf. HIV/AIDS and HCV in prisons: A select annotated bibliography. Ottawa, Ont: International Affairs Directorate, Health Canada, 2005.
Znajdź pełny tekst źródłaOkita, Kiwamu, red. HCV/Oxidative Stress and Liver Disease. Tokyo: Springer Japan, 2003. http://dx.doi.org/10.1007/978-4-431-67005-6.
Pełny tekst źródłaKiwamu, Okita, red. HCV/oxidative stress and liver disease. Tokyo: Springer, 2003.
Znajdź pełny tekst źródłaname, No. HCV/oxidative stress and liver disease. Tokyo: Springer, 2003.
Znajdź pełny tekst źródłaSofia, Michael J., red. HCV: The Journey from Discovery to a Cure. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-28400-8.
Pełny tekst źródłaCzęści książek na temat "HCV"
Vachon, Marie-Louise C., Alicia C. Stivala i Douglas T. Dieterich. "HIV/HCV and HIV/HBV Co-infections". W Mount Sinai Expert Guides: Hepatology, 78–95. Oxford, UK: John Wiley & Sons, Ltd, 2014. http://dx.doi.org/10.1002/9781118748626.ch7.
Pełny tekst źródłaWeiner, Amy J., Michael M. Thaler, Kevin Crawford, Joe Kansopon, Keith Ching, J. Eric Hall, Fang Hu, David Chien i Michael Houghton. "HCV-positive, HIV-1-negative Mothers Transmit HCV". W Viral Hepatitis and Liver Disease, 463–67. Tokyo: Springer Japan, 1994. http://dx.doi.org/10.1007/978-4-431-68255-4_118.
Pełny tekst źródłaCoffin, Carla S., i Norah A. Terrault. "Treatment of HCV, HDV, or HIV Coinfection". W Hepatitis B Virus and Liver Disease, 239–62. Singapore: Springer Singapore, 2017. http://dx.doi.org/10.1007/978-981-10-4843-2_13.
Pełny tekst źródłaZhou, Kali, i Norah A. Terrault. "Treatment of HCV, HDV, or HIV Coinfections". W Hepatitis B Virus and Liver Disease, 339–73. Singapore: Springer Singapore, 2021. http://dx.doi.org/10.1007/978-981-16-3615-8_15.
Pełny tekst źródłaTerrault, Norah A. "Hepatic Transplantation and HBV, HCV, and HIV Infections". W Sherlock's Diseases of the Liver and Biliary System, 758–80. Chichester, UK: John Wiley & Sons, Ltd, 2018. http://dx.doi.org/10.1002/9781119237662.ch38.
Pełny tekst źródłaSalmon-Ceron, Dominique, J. E. Arends, C. Leoni, C. Solas i G. Peytavin. "HIV/HCV Coinfection: Current Challenges". W Viral Hepatitis: Chronic Hepatitis C, 141–57. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-03757-4_7.
Pełny tekst źródłaPerez-Alamino, Rodolfo. "Hepatitis Arthritis: HBV and HCV". W Infections and the Rheumatic Diseases, 107–12. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-23311-2_10.
Pełny tekst źródłaIngiliz, Patrick, Maud Lemoine i Yves Benhamou. "Chronic HCV and HIV Coinfection". W Chronic Hepatitis C Virus, 75–91. New York, NY: Springer New York, 2011. http://dx.doi.org/10.1007/978-1-4614-1192-5_7.
Pełny tekst źródłaPereira, Luis F., John J. Faragon, Antoine Douaihy i Courtney E. Kandler. "Treatment of Comorbid HIV/HCV". W HIV Psychiatry, 477–97. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-80665-1_18.
Pełny tekst źródłaBeard, Michael R. "HCV Replication". W Advanced Therapy for Hepatitis C, 1–11. Oxford, UK: Wiley-Blackwell, 2011. http://dx.doi.org/10.1002/9781444346343.ch1.
Pełny tekst źródłaStreszczenia konferencji na temat "HCV"
BUZUTTI, P. C., i F. M. T. BINHARDI. "IMPLICAÇÕES DA CO-INFECÇÃO DA DENGUE EM PACIENTES CRONICAMENTE INFECTADOS PELOS VÍRUS HBV E HCV NA REGIÃO DE SÃO JOSÉ DO RIO PRETO-SP". W III Mostra Dos Trabalhos De Conclusão De Curso Da Especialização Em Vigilância Laboratorial Em Saúde Pública. Agron Science, 2022. http://dx.doi.org/10.53934/101021-2.
Pełny tekst źródłaDarvishian, Maryam, Carmine Rossi, Stanley Wong, Amanda Yu, Jason Wong, Jane Buxton, Mark Gilbert i in. "P386 Cancer risk among people with HIV, HBV and/or HCV infections". W Abstracts for the STI & HIV World Congress (Joint Meeting of the 23rd ISSTDR and 20th IUSTI), July 14–17, 2019, Vancouver, Canada. BMJ Publishing Group Ltd, 2019. http://dx.doi.org/10.1136/sextrans-2019-sti.481.
Pełny tekst źródłaFerreira da Silva, Giovanna, Marcello do Couto Dias, Irley Karoline Seixas Paiva, Mércia Ferreira Ribeiro, Katarine Antonia dos Santos Barile i Carlos Eduardo de Melo Amaral. "AVALIAÇÃO DO TESTE SUPLEMENTAR GEENIUS HCV SUPPLEMENTAL ASSAY NA DISPARIDADE ENTRE RESULTADO DE TRIAGEM SOROLÓGICO-MOLECULAR PARA O VÍRUS DA HEPATITE C". W Congresso Brasileiro de Inovação em Microbiologia. Congresse.me, 2022. http://dx.doi.org/10.54265/rnfk1700.
Pełny tekst źródłaYarraguntla, Nireekshith, Naveena Tirumala, Syed Shameem i K. srinivasa rao. "Detection of Hepatitis viruses (HBV, HAV, HCV) in serum using MEMS based Bio-Sensor". W 2018 Second International Conference on Computing Methodologies and Communication (ICCMC). IEEE, 2018. http://dx.doi.org/10.1109/iccmc.2018.8487679.
Pełny tekst źródłaCorinaldesi, G., R. Sentinelli, S. Guglielmi, V. Barocci, S. Castelletti, I. Pierantonelli, S. Gemini, A. Riva, M. Martini i A. Costantini. "CP-059 Efficacy and cost of direct acting antivirals for the treatment of hcv infection among HCV monoinfected and HIV/HCV coinfected patients in real life setting". W 22nd EAHP Congress 22–24 March 2017 Cannes, France. British Medical Journal Publishing Group, 2017. http://dx.doi.org/10.1136/ejhpharm-2017-000640.58.
Pełny tekst źródłaRocha, Daniele, Elisabete Andrade, Marcela Fontana, Marisa Ribeiro, Elaine Motta, Daniela Godoy, Antonio Ferreira, Rodrigo Brindeiro, Amilcar Tanuri i Patricia Alvarez. "Desenvolvimento de uma nova partícula calibradora para o Kit NAT HIV/HCV/HBV Bio-Manguinhos". W III Seminário Anual Científico e Tecnológico de Bio-Manguinhos. Instituto de Tecnologia em Imunobiológicos, 2016. http://dx.doi.org/10.35259/isi.sact.2016_27367.
Pełny tekst źródłaKudrjavtseva, E. N., M. I. Korabelnikova, T. A. Semenenko, Ya V. Panasyuk i S. N. Kuzin. "THE IMPORTANCE OF ANTI-HCV SCREENING IN PATIENTS OF LARGE MULTIFIELD HOSPITALS". W Molecular Diagnostics and Biosafety. Federal Budget Institute of Science 'Central Research Institute for Epidemiology', 2020. http://dx.doi.org/10.36233/978-5-9900432-9-9-49.
Pełny tekst źródłaWu, Xindong. "The HCV induction algorithm". W the 1993 ACM conference. New York, New York, USA: ACM Press, 1993. http://dx.doi.org/10.1145/170791.170825.
Pełny tekst źródłaFarias, Bruna Brandão de, Imman Fuad Khattab Hassan, Camila Tlustak Soares i Maristela Böhlke. "Crioglobulinemia associada ao HCV". W 13º Congresso Gaúcho de Clínica Médica. São Paulo: Editora Edgard Blücher, 2016. http://dx.doi.org/10.5151/medpro-xiiicgcm-1459187062.
Pełny tekst źródłaPrasetyo, Afiono Agung. "VLPs of HCV local isolates for HCV immunoassay diagnostic approach in Indonesia". W INTERNATIONAL CONFERENCE ON ENGINEERING, SCIENCE AND NANOTECHNOLOGY 2016 (ICESNANO 2016). Author(s), 2017. http://dx.doi.org/10.1063/1.4968353.
Pełny tekst źródłaRaporty organizacyjne na temat "HCV"
Hung, Hsuan-Yu, i Chung-Yu Chen. The impact of Sofosbuvir/Velpatasvir/Voxilaprevir treatment on serum hyperglycemia in HCV infections: A Systematic Review. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, grudzień 2021. http://dx.doi.org/10.37766/inplasy2021.12.0109.
Pełny tekst źródłaMiller, Sarah, Autumn Spight, Mahogany Freeman i Sharon Little. Monitoring Adherence to HCV Screening Among the Baby Boomer Population. University of Tennessee Health Science Center, maj 2022. http://dx.doi.org/10.21007/con.dnp.2022.0040.
Pełny tekst źródłaMensch, Barbara, i Erica Soler-Hampejsek. Characteristics associated with HIV and HSV-2 among adolescents in Malawi. Population Council, 2017. http://dx.doi.org/10.31899/hiv6.1007.
Pełny tekst źródłaMensch, Barbara, i Erica Soler-Hampejsek. Rates of HIV and HSV-2 among young people in Machinga, Malawi. Population Council, 2017. http://dx.doi.org/10.31899/hiv6.1027.
Pełny tekst źródłaSmith, Lynette M., Nicholas A. Hein i Danstan S. Bagenda. Cash transfers and HIV/HSV-2 prevalence: a replication of a cluster randomized trial in Malawi. International Initiative for Impact Evaluation (3ie), październik 2017. http://dx.doi.org/10.23846/rps0012.
Pełny tekst źródłaYu, Fang, Nicholas A. Hein i Danstan S. Bagenda. Preventing HIV and HSV-2 through improving knowledge and attitudes: a replication study of a multicomponent intervention in Zimbabwe. International Initiative for Impact Evaluation (3ie), marzec 2018. http://dx.doi.org/10.23846/rps0016.
Pełny tekst źródłaRinke, Helen Mae. HCM Interface. Office of Scientific and Technical Information (OSTI), kwiecień 2020. http://dx.doi.org/10.2172/1617344.
Pełny tekst źródłaPinter, Abraham. HIV Vaccines Based on Novel MULV-HIV Fusion Proteins. Fort Belvoir, VA: Defense Technical Information Center, lipiec 1999. http://dx.doi.org/10.21236/ada373677.
Pełny tekst źródłaBingamon, Brian Michael. HIV Mosaic Vaccine. Office of Scientific and Technical Information (OSTI), grudzień 2019. http://dx.doi.org/10.2172/1581247.
Pełny tekst źródłaKanki, Phyllis. Interactions of HIV-1 and HIV-2 in West Africa. Fort Belvoir, VA: Defense Technical Information Center, lipiec 1999. http://dx.doi.org/10.21236/ada367779.
Pełny tekst źródła